Katharine D Barnard1, Amanda J Young, Norman R Waugh. 1. NIHR Evaluation Trials and Studies Coordinating Centre, University of Southampton, Southampton Science Park, Chilworth, Southampton SO16 7NS UK. k.barnard@southampton.ac.uk.
Abstract
BACKGROUND: Aim - to survey members of Diabetes UK who had Type 2 diabetes and who used self monitoring of blood glucose (SMBG), to elicit their views on its usefulness in the management of their diabetes, and how they used the results. A questionnaire was developed for the Diabetes UK website. The questionnaire was posted on the Diabetes UK website until over 500 people had responded. Questions asked users to specify the benefits gained from SMBG, and how these benefits were achieved. We carried out both quantitative analysis and a thematic analysis for the open ended free-text questions. FINDINGS: 554 participants completed the survey, of whom 289 (52.2%) were male. 20% of respondents were recently diagnosed (< 6 months). Frequency of SMBG varied, with 43% of participants testing between once and four times a day and 22% testing less than once a month or for occasional periods.80% of respondents reported high satisfaction with SMBG, and reported feeling more 'in control' of their diabetes management using it. The most frequently reported use of SMBG was to make adjustments to food intake or confirm a hyperglycaemic episode.Women were significantly more likely to report feelings of guilt or self-chastisement associated with out of range readings (p = < .001). CONCLUSION: SMBG was clearly of benefit to this group of confirmed users, who used the results to adjust diet, physical activity or medications. However many individuals (particularly women) reported feelings of anxiety and depression associated with its use.
BACKGROUND: Aim - to survey members of Diabetes UK who had Type 2 diabetes and who used self monitoring of blood glucose (SMBG), to elicit their views on its usefulness in the management of their diabetes, and how they used the results. A questionnaire was developed for the Diabetes UK website. The questionnaire was posted on the Diabetes UK website until over 500 people had responded. Questions asked users to specify the benefits gained from SMBG, and how these benefits were achieved. We carried out both quantitative analysis and a thematic analysis for the open ended free-text questions. FINDINGS: 554 participants completed the survey, of whom 289 (52.2%) were male. 20% of respondents were recently diagnosed (< 6 months). Frequency of SMBG varied, with 43% of participants testing between once and four times a day and 22% testing less than once a month or for occasional periods.80% of respondents reported high satisfaction with SMBG, and reported feeling more 'in control' of their diabetes management using it. The most frequently reported use of SMBG was to make adjustments to food intake or confirm a hyperglycaemic episode.Women were significantly more likely to report feelings of guilt or self-chastisement associated with out of range readings (p = < .001). CONCLUSION: SMBG was clearly of benefit to this group of confirmed users, who used the results to adjust diet, physical activity or medications. However many individuals (particularly women) reported feelings of anxiety and depression associated with its use.
Authors: Andrew J Karter; Melissa M Parker; Howard H Moffet; Michele M Spence; James Chan; Susan L Ettner; Joe V Selby Journal: Diabetes Care Date: 2006-08 Impact factor: 19.112
Authors: David C Klonoff; Lawrence Blonde; George Cembrowski; Antonio Roberto Chacra; Guillaume Charpentier; Stephen Colagiuri; George Dailey; Robert A Gabbay; Lutz Heinemann; David Kerr; Antonio Nicolucci; William Polonsky; Oliver Schnell; Robert Vigersky; Jean-François Yale Journal: J Diabetes Sci Technol Date: 2011-11-01
Authors: Elizabeth R Pfoh; Debra Linfield; Sidra L Speaker; Joud S Roufael; Chen Yan; Anita D Misra-Hebert; Michael B Rothberg Journal: J Gen Intern Med Date: 2021-08-13 Impact factor: 6.473
Authors: Wenxin Wang; Céline van Lint; Sandra van Dijk; Willem-Paul Brinkman; Ton Jm Rövekamp; Mark A Neerincx; Ton J Rabelink; Paul Jm van der Boog Journal: J Med Internet Res Date: 2017-09-26 Impact factor: 5.428
Authors: Céline L van Lint; Paul Jm van der Boog; Wenxin Wang; Willem-Paul Brinkman; Ton Jm Rövekamp; Mark A Neerincx; Ton J Rabelink; Sandra van Dijk Journal: Patient Prefer Adherence Date: 2015-12-07 Impact factor: 2.711